The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Community Acquired Pneumonia (CAP) Market Research Report 2025
Synopsis
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
The global Community Acquired Pneumonia (CAP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.
This report aims to provide a comprehensive presentation of the global market for Community Acquired Pneumonia (CAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community Acquired Pneumonia (CAP).
Report Scope
The Community Acquired Pneumonia (CAP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Community Acquired Pneumonia (CAP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Community Acquired Pneumonia (CAP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals
Segment by Type
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures
Segment by Application
Hospitals and Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community Acquired Pneumonia (CAP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
The global Community Acquired Pneumonia (CAP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.
This report aims to provide a comprehensive presentation of the global market for Community Acquired Pneumonia (CAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community Acquired Pneumonia (CAP).
Report Scope
The Community Acquired Pneumonia (CAP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Community Acquired Pneumonia (CAP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Community Acquired Pneumonia (CAP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals
Segment by Type
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures
Segment by Application
Hospitals and Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community Acquired Pneumonia (CAP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chest X-ray/Radiography
1.2.3 Sputum Gram Stain and/or Culture
1.2.4 Blood Cultures
1.3 Market by Application
1.3.1 Global Community Acquired Pneumonia (CAP) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Community Acquired Pneumonia (CAP) Market Perspective (2019-2030)
2.2 Community Acquired Pneumonia (CAP) Growth Trends by Region
2.2.1 Global Community Acquired Pneumonia (CAP) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Community Acquired Pneumonia (CAP) Historic Market Size by Region (2019-2024)
2.2.3 Community Acquired Pneumonia (CAP) Forecasted Market Size by Region (2025-2030)
2.3 Community Acquired Pneumonia (CAP) Market Dynamics
2.3.1 Community Acquired Pneumonia (CAP) Industry Trends
2.3.2 Community Acquired Pneumonia (CAP) Market Drivers
2.3.3 Community Acquired Pneumonia (CAP) Market Challenges
2.3.4 Community Acquired Pneumonia (CAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue
3.1.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue (2019-2024)
3.1.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Players (2019-2024)
3.2 Global Community Acquired Pneumonia (CAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Community Acquired Pneumonia (CAP) Revenue
3.4 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio
3.4.1 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Community Acquired Pneumonia (CAP) Revenue in 2023
3.5 Community Acquired Pneumonia (CAP) Key Players Head office and Area Served
3.6 Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
3.7 Date of Enter into Community Acquired Pneumonia (CAP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Community Acquired Pneumonia (CAP) Breakdown Data by Type
4.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Type (2019-2024)
4.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2025-2030)
5 Community Acquired Pneumonia (CAP) Breakdown Data by Application
5.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Application (2019-2024)
5.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Community Acquired Pneumonia (CAP) Market Size (2019-2030)
6.2 North America Community Acquired Pneumonia (CAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024)
6.4 North America Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Community Acquired Pneumonia (CAP) Market Size (2019-2030)
7.2 Europe Community Acquired Pneumonia (CAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024)
7.4 Europe Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size (2019-2030)
8.2 Asia-Pacific Community Acquired Pneumonia (CAP) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2019-2024)
8.4 Asia-Pacific Community Acquired Pneumonia (CAP) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Community Acquired Pneumonia (CAP) Market Size (2019-2030)
9.2 Latin America Community Acquired Pneumonia (CAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024)
9.4 Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size (2019-2030)
10.2 Middle East & Africa Community Acquired Pneumonia (CAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024)
10.4 Middle East & Africa Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Community Acquired Pneumonia (CAP) Introduction
11.1.4 Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Detail
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Introduction
11.2.4 Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.2.5 Astrazeneca Recent Development
11.3 Bioaegis Therapeutics
11.3.1 Bioaegis Therapeutics Company Detail
11.3.2 Bioaegis Therapeutics Business Overview
11.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.3.4 Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.3.5 Bioaegis Therapeutics Recent Development
11.4 Biotest
11.4.1 Biotest Company Detail
11.4.2 Biotest Business Overview
11.4.3 Biotest Community Acquired Pneumonia (CAP) Introduction
11.4.4 Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.4.5 Biotest Recent Development
11.5 C10 Pharma
11.5.1 C10 Pharma Company Detail
11.5.2 C10 Pharma Business Overview
11.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Introduction
11.5.4 C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.5.5 C10 Pharma Recent Development
11.6 Kyorin Pharmaceutical
11.6.1 Kyorin Pharmaceutical Company Detail
11.6.2 Kyorin Pharmaceutical Business Overview
11.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Introduction
11.6.4 Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.6.5 Kyorin Pharmaceutical Recent Development
11.7 Melinta Therapeutics
11.7.1 Melinta Therapeutics Company Detail
11.7.2 Melinta Therapeutics Business Overview
11.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.7.4 Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.7.5 Melinta Therapeutics Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Community Acquired Pneumonia (CAP) Introduction
11.8.4 Merck Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.8.5 Merck Recent Development
11.9 Nabriva Therapeutics
11.9.1 Nabriva Therapeutics Company Detail
11.9.2 Nabriva Therapeutics Business Overview
11.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Introduction
11.9.4 Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.9.5 Nabriva Therapeutics Recent Development
11.10 Paratek Pharmaceuticals
11.10.1 Paratek Pharmaceuticals Company Detail
11.10.2 Paratek Pharmaceuticals Business Overview
11.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Introduction
11.10.4 Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024)
11.10.5 Paratek Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
